Reversible male birth control injectable lasts 2 years, moves to phase 2 human trials
SMRTR summary
A new male contraceptive, ADAM™, has moved to Phase 2 clinical trials after successful initial testing. The injectable hydrogel blocks sperm for up to two years, offering a potential alternative to condoms and vasectomy with a 99.8-100% reduction in motile sperm within 30 days of implantation.
SMRTR provides this summary for quick context. The original article belongs to Interesting Engineering.
Read the original article